Parkinson's disease

Researchers found that blocking a protein called Activin A can prevent dyskinesia, a debilitating side effect of Parkinson's treatment, potentially allowing patients to stay on levodopa longer without developing uncontrollable movements.

Researchers developed a model using blood proteins and clinical data to predict Parkinson's disease risk up to 15 years before symptoms appear. This early detection could help prevent or delay the progression of the disease.

Researchers at the University of Florida developed an AI-powered video-processing system that analyzes hand movement tests to detect subtle changes in Parkinson’s disease symptoms, enabling more precise and accessible monitoring of disease progression from home.

A recent study has uncovered a significant link between the brain chemical dopamine and our ability to understand and attribute mental states to ourselves and others.

Visual hallucinations in Parkinson’s disease are linked to significant cholinergic deficiencies in the left ventral visual stream and left superior temporal lobe, highlighting potential targets for treatment.

Older adults with new-onset anxiety are more than twice as likely to develop Parkinson's disease, suggesting anxiety could be an early indicator for the neurodegenerative disorder.

Researchers found that dopamine is crucial for social cognition, including understanding emotions and mental states. Dopamine imbalances, as seen in disorders like Parkinson's, directly cause social difficulties, suggesting potential for dopamine-based treatments to improve social skills.

Scientists have discovered how a key enzyme, PINK1, is switched on by interacting with specific parts of cell machinery, which helps protect brain cells from Parkinson's disease.

Coffee drinkers have a significantly lower risk of developing Parkinson’s disease, with the highest consumers nearly 40% less likely to develop the condition compared to non-drinkers.

Researchers at the Salk Institute found that cannabinol (CBN) and its derivatives could protect brain cells from aging and damage, showing potential for treating neurological disorders like Alzheimer's and traumatic brain injuries. These findings suggest new therapeutic avenues for neurodegeneration.

Researchers have discovered a new genetic variant, RAB32 Ser71Arg, linked to Parkinson's disease across several countries. This variant interacts with proteins affecting dopamine levels and cell functions, providing insights into the disease's molecular pathways and potential new avenues for treatment.

In a pioneering study published in Nature Human Behavior, researchers from Virginia Tech and collaborators have made significant strides in understanding the neurochemical basis of social interactions, focusing on the roles of dopamine and serotonin.